Company intelligence / Profile preview
J-Pharma
Yokohama, Kanagawa, Japanj-pharma.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Other
01
Overview
J‑Pharma’s lead compound nanvuranlat met the primary endpoint in a phase II study in Japan for advanced biliary tract cancer patients resistant to Gemcitabine/Cisplatin. The company plans a global phase III trial starting in 2024 and expects regulatory submissions to FDA/EMA by 2026–27. Nanvuranlat has shown significant improvement in progression-free survival and long-term safety/tolerability. Indication expansion into first-line BTC therapy and other cancers (colorectal, kidney, brain) as well as autoimmune diseases are planned.
- Therapeutic areas
- ImmunologyNeurologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
OSAKA UNIVERSITYYOKOHAMA CITY UNIVERSITYGeorgetown UniversityKanazawa UniversityOHARA Pharmaceutical Co., Ltd.SPERAPHARMA Inc.
Beyond the preview
Go deeper on J-Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on J-Pharma.